类风湿关节炎中阿达木单抗的治疗性血清水平:一项随机III期试验数据的探索性分析
基于48周随机III期试验中未经TNF抑制剂治疗的活动性类风湿关节炎患者数据,探索阿达木单抗谷浓度与疾病活动度的关联。结果显示谷浓度≥3.9 mg/L与DAS28缓解相关(OR 3.88),第12周谷浓度≥3.5 mg/L与第24周低疾病活动度及第48周缓解相关,结论认为谷浓度高于4.0 mg/L可作为治疗药物监测的下限目标水平。
要点
- 阿达木单抗谷浓度≥3.9 mg/L与DAS28缓解相关(OR 3.88,95%CI 1.80-8.38,p<0.001)。
- 第12周谷浓度≥3.5 mg/L与第24周低疾病活动度相关(OR 2.62,95%CI 1.50-4.56,p<0.001)。
- 阿达木单抗谷浓度高于4.0 mg/L可考虑作为治疗药物监测的下限目标水平。
核心结论
- 阿达木单抗谷浓度高于4.0 mg/L与治疗第一年内的缓解/低疾病活动度相关,可考虑作为阿达木单抗治疗药物监测的下限目标水平。
研究设计与样本
- 一项48周随机III期试验的探索性分析,纳入未经肿瘤坏死因子抑制剂治疗的活动性类风湿关节炎并开始阿达木单抗治疗的患者。
主要发现
- 第12、24、48周分别纵向记录336、330和302例患者的阿达木单抗谷浓度,所有患者均联用甲氨蝶呤。
- 阿达木单抗谷浓度中位数第12周为6.4 mg/L(IQR 3.4-9.5),第24周为7.5 mg/L(IQR 3.5-10.9),第48周为7.6 mg/L(IQR 3.6-12.0)。
- 第12、24、48周系列血清样本中,谷浓度≥3.9 mg/L与DAS28缓解相关(OR 3.88,95%CI 1.80-8.38,p<0.001)及较低的CRP水平相关(p<0.001)。
- 第12周谷浓度≥3.5 mg/L与第24周DAS28低疾病活动度相关(OR 2.62,95%CI 1.50-4.56,p<0.001)及第48周缓解相关(OR 1.99,95%CI 1.02-3.88,p=0.04),并与两个时间点的较低CRP水平相关(p<0.001)。
关键数值与推荐
- 谷浓度≥3.9 mg/L与DAS28缓解相关(OR 3.88,95%CI 1.80-8.38,p<0.001)。
- 第12周谷浓度≥3.5 mg/L与第24周DAS28低疾病活动度相关(OR 2.62,95%CI 1.50-4.56,p<0.001)及第48周缓解相关(OR 1.99,95%CI 1.02-3.88,p=0.04)。
- 阿达木单抗谷浓度高于4.0 mg/L可考虑作为治疗药物监测的下限目标水平。
临床怎么用
- 作者认为阿达木单抗谷浓度高于4.0 mg/L可考虑作为阿达木单抗治疗药物监测的下限目标水平。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The objectives of this study are to identify a therapeutic serum level for adalimumab associated with remission and low disease activity in patients with rheumatoid arthritis. METHODS: Associations between serum adalimumab trough levels and disease activity were examined using longitudinal data from a 48-week randomised phase III trial including patients with tumour necrosis factor inhibitor-naïve rheumatoid arthritis with active disease starting adalimumab treatment. Disease activity was classified according to 28-joint Disease Activity Score (DAS28)-erythrocyte sedimentation rate and C reactive protein (CRP) levels. RESULTS: Adalimumab trough levels were recorded longitudinally for 336, 330 and 302 patients at weeks 12, 24 and 48, respectively. All patients received concomitant methotrexate. Median adalimumab trough levels were 6.4 mg/L (IQR 3.4-9.5) at week 12, 7.5 mg/L (IQR 3.5-10.9) at week 24 and 7.6 mg/L (IQR 3.6-12.0) at week 48. In serial serum samples from weeks 12, 24 and 48, trough levels ≥3.9 mg/L were associated with DAS28 remission (OR 3.88 (95% CI 1.80, 8.38), p<0.001) and lower CRP levels (p<0.001). Week 12 trough levels ≥3.5 mg/L were associated with DAS28 low disease activity at week 24 (OR 2.62 (1.50, 4.56), p<0.001) and remission at week 48 (OR 1.99 (1.02, 3.88), p=0.04), as well as lower CRP levels at both time points (p<0.001). CONCLUSION: Adalimumab trough levels above 4.0 mg/L were associated with remission/low disease activity throughout the first year of adalimumab therapy and can be considered a lower target level for therapeutic drug monitoring of adalimumab therapy.
引用
- Gehin JE, Klaasen RA, Klami Kristianslund E, et al. Therapeutic serum level for adalimumab in rheumatoid arthritis: explorative analyses of data from a randomised phase III trial. RMD Open. 2024. PMID: 39537558. doi:10.1136/rmdopen-2024-004888
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。